Zenas BioPharma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1000 Winter St Ste 1200, Waltham, Massac...Phone Number
(857) 271-2954Website
www.zenasbio.comRevenue
<$5 MillionStock Symbol
ZBIOIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Zenas BioPharma
Zenas BioPharma is dedicated to developing therapies for patients with autoimmune diseases, aiming to address significant unmet medical needs and transform their lives. The company is advancing its investigational drug, Obexelimab, which targets B cell activity to help manage various autoimmune conditions. They prioritize understanding the experiences of patients and caregivers to create impactful therapies. Zenas BioPharma is committed to leading in the field of autoimmune disease treatment through its experienced team and innovative approach.Explore more
Zenas BioPharma Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zenas BioPharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Zenas BioPharma recently announced quarterly report
Check out if Zenas BioPharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Zenas BioPharma launches new products
Zenas BioPharma, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Zenas BioPharma has new funding data
Congratulate Masked Content for being promoted to Masked Content at Zenas BioPharma
Check if Zenas BioPharma has recently received funding, and reach out quickly before it becomes old news!
Click to see if Zenas BioPharma had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Zenas BioPharma
Find 3 more new buyers
Compare Similar Companies to Zenas BioPharma
Compare insights from companies similar to Zenas BioPharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$50.7M
51-200
Private
-
1999
AO
Aram OganesianVice President, Clinical Pharmacology & Nonclinical Development
<$5M
51-200
Private
$170M
2019
Company Profile Activity
Activity Insights
Zenas BioPharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Zenas BioPharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Zenas BioPharma.
Zenas BioPharma financials insights
Gather financial insights about Zenas BioPharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series B
$118M
2024
Series C
$200M
Zenas BioPharma Tech Stack
A closer look at the technologies used by Zenas BioPharma
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Earnings
Earnings, Finance
Zenas BioPharma News & Media
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on September 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchaseZenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Zenas BioPharma, Inc. (ZBIO) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 4:20 PM EDTCompany ParticipantsLeon Moulder - Founder, CEO...Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host an Obexelimab IgG4-RD Investor Event virtually on Tuesday, September 29, 2026, from 8:00 – 9:30 a.m. ET.Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management’s presentations at the following investor conferences:
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Zenas BioPharma
Sign Up For FreeTo access detailed company insights
Zenas BioPharma is dedicated to developing therapies for patients with autoimmune diseases, aiming to address significant unmet medical needs and transform their lives. The company is advancing its investigational drug, Obexelimab, which targets B cell activity to help manage various autoimmune conditions. They prioritize understanding the experien... Read More
